| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-55 |
| filingDate |
2017-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a230d9004fab0e14c557a9eef6b21f69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31e64cb52a4c9ea1d2fdfddc09aaa7be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0300bcd095b16f5845d5e6b611004ce4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_146d44431b3b608cb3575edbd26cb5ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3a94da7d59c553c106c9b5750f2bfa7 |
| publicationDate |
2017-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017137485-A1 |
| titleOfInvention |
Interleukin-2 muteins for the expansion of t-regulatory cells |
| abstract |
Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10676516-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10174091-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10174092-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11091526-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11091527-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11466068-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779632-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11739146-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10946068-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11491205-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10961310-B2 |
| priorityDate |
2013-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |